Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Meta Expands AI Training With Employee Activity Tracking Tools 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
NEW HAVEN, Conn., March 03, 2016 -- Melinta Therapeutics today announced that Dr. Eugene Sun, the Company’s interim Chief Executive Officer, will present a clinical and corporate update at BioCentury’s 23rd annual Future Leaders in the Biotech Industry conference at 11:30 a.m. ET on March 11, 2016. The conference is being held at the Millennium Broadway Hotel & Conference Center in New York City, NY.
The Future Leaders in the Biotech Industry conference connects Wall Street and pharmaceutical executives with private and public biotechnology companies, offering new investment and partnering opportunities. Last year, more than 500 delegates, representing top financial institutions, pharmaceutical business development executives, and high net worth investors congregated at Future Leaders. For more information, or to request a one-on-one meeting with Melinta, please visit: http://www.biocentury.com.
About Melinta Therapeutics
Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development of novel antibiotics that provide new and better therapeutic solutions. Melinta is rapidly progressing its late-stage investigational antibiotic, Baxdela, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Melinta is committed to developing, through the application of Nobel Prize-winning science, a new class of antibiotics designed to overcome the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and Escherichia coli), which cause the majority of life-threatening hospital infections.
Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners (www.vaterahealthcare.com) and Malin Corporation plc (www.malinplc.com) among other private investors. The company is headquartered in New Haven, CT with offices in Lincolnshire, IL. Visit www.melinta.com for more information.
Melinta Therapeutics Kathy Powell (312) 724-9400 [email protected] Media Contact Aline Sherwood (312) 238-8957 [email protected]
